뒤로
Mustang Bio Inc (MBIO) 수입
MBIO 주가 차트
MBIO 수입
Mustang Bio Inc
$0.77
1.96%
$0.01
종가: Apr 02, 16:00:00 GMT-4
$0.77
0%
$0
애프터마켓: Apr 02, 20:00:00 GMT-4
최신 수익 결과: Q4 '24
보고됨: 2025-03-28
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
MBIO의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Mustang Bio Inc MBIO의 지난 분기 매출 실적은 어땠나요?
Mustang Bio Inc의 매출 추정치는 얼마인가요?
Mustang Bio Inc의 수익 품질 점수는 얼마인가요?
Mustang Bio Inc는 언제 수익을 보고하나요?
Mustang Bio Inc의 예상 수익은 얼마인가요?
Mustang Bio Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.7601
시가
$0.7702
일일 범위
$0.74 - $0.79
52주 범위
$0.531 - $7
거래량
56.6K
평균 거래량
169.7K
배당수익률
--
EPS(TTM)
-1.26
시가총액
$5.6M
MBIO란 무엇인가요?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.